An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Eligibility Criteria

• * Have a diagnosis of adult-onset RA for at least 3 months prior to screening as defined by the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria.
• * Have moderately-to-severely active RA at screening and baseline, defined by the presence of
• * ≥6 swollen joints based on 66 joint count, and
• * ≥6 tender joints based on 68 joint count.
• * Have had a history of failure (an inadequate response, intolerance, or loss of response) to at least 1 conventional synthetic disease modifying anti rheumatic drug (csDMARD) and either 1 biologic (bDMARD), or targeted synthetic (tsDMARD) treatment.
• * Have Class IV RA according to ACR revised criteria
• * Have presence of 1 or more significant concurrent medical conditions per investigator judgment, including but not limited to
• * poorly controlled diabetes or hypertension
• * chronic kidney disease stage IIIa or IIIb, IV, or V
• * symptomatic heart failure according to New York Heart Association class II, III, or IV
• * myocardial infarction,unstable angina pectoris, stroke, or transient ischemic attack within the past 12 months before randomization
• * severe chronic pulmonary disease, for example, requiring oxygen therapy
• * major chronic inflammatory disease or connective tissue disease other than RA, including but not limited to
• * systemic lupus erythematosus
• * psoriatic arthritis
• * axial spondyloarthritis,including ankylosing spondylitis and non-radiographic axial spondyloarthritis
• * reactive arthritis
• * gout
• * scleroderma
• * polymyositis
• * dermatomyositis
• * active fibromyalgia, or
• * multiple sclerosis